Potnis Chinmay S, Chauhan Rajat, Kalbfleisch Theodore S, Alexander Evan, Eichhold Lindsay, Bansal Meenakshi, Grapperhaus Craig A, Keynton Robert S, Linder Mark W, Gupta Gautam
Department of Chemistry, University of Louisville Louisville 40292 Kentucky USA.
Department of Chemical Engineering, University of Louisville Louisville 40292 Kentucky USA
RSC Adv. 2022 Oct 13;12(45):29399-29404. doi: 10.1039/d2ra05862f. eCollection 2022 Oct 11.
Previously, our group had demonstrated long term stabilization of protein biomarkers using BioCaRGOS, a silica sol-gel technology. Herein, we describe workflow modifications to allow for extraction of cell free DNA (cfDNA) from primary samples containing working concentrations of BioCaRGOS, as well as the compatibility of BioCaRGOS with droplet digital PCR (ddPCR) analysis for pancreatic cancer biomarkers , KRAS circulating tumor DNA (ctDNA). Preliminary attempts to extract ctDNA from BioCaRGOS containing samples demonstrated interference in the extraction of primary samples and the interference with ddPCR analysis when BioCaRGOS was directly introduced to stabilize sample extracts. In our modified technique, we have minimized the interference caused by methanol with ddPCR by complete removal of methanol from the activated BioCaRGOS formulation prior to addition to the biospecimen or ctDNA extract. Interference of the silica matrix present in BioCaRGOS with ctDNA extraction was eliminated through the introduction of invert filtration of the sample prior to extraction. These modifications to the workflow of BioCaRGOS containing samples allow for use of BioCaRGOS for stabilization of trace quantities of nucleic acid biomarkers such as plasma ctDNA, while retaining the capability to extract the biomarker and quantify based on ddPCR.
此前,我们团队已利用BioCaRGOS(一种硅溶胶-凝胶技术)证明了蛋白质生物标志物的长期稳定性。在此,我们描述了工作流程的改进,以允许从含有工作浓度BioCaRGOS的原始样本中提取游离DNA(cfDNA),以及BioCaRGOS与用于胰腺癌生物标志物KRAS循环肿瘤DNA(ctDNA)的液滴数字PCR(ddPCR)分析的兼容性。从含有BioCaRGOS的样本中提取ctDNA的初步尝试表明,当直接引入BioCaRGOS以稳定样本提取物时,会干扰原始样本的提取以及ddPCR分析。在我们改进的技术中,通过在将活化的BioCaRGOS制剂添加到生物样本或ctDNA提取物之前完全去除甲醇,我们将甲醇对ddPCR的干扰降至最低。通过在提取前对样品进行反向过滤,消除了BioCaRGOS中存在的二氧化硅基质对ctDNA提取的干扰。对含有BioCaRGOS的样本工作流程的这些改进,使得BioCaRGOS能够用于稳定痕量核酸生物标志物,如血浆ctDNA,同时保留提取生物标志物并基于ddPCR进行定量的能力。